Skip to main content

Does Rituxan cause hair loss?

Medically reviewed by Kristianne Hannemann, PharmD. Last updated on July 13, 2024.

Official answer

by drugclasses.com

It’s possible for Rituxan (rituximab) to cause hair loss. This includes losing hair anywhere on your body, such as your head, legs, eyebrows, and eyelashes. You could experience patches of hair loss or hair thinning. Not everyone who takes Rituxan will experience hair loss as a side effect. If you do have hair loss from Rituxan, it will likely grow back after you finish your treatment.

How common is hair loss from Rituxan?

Hair loss (alopecia) does not seem to be a common side effect of Rituxan. A systematic review and meta-analysis of clinical trials found that Rituxan rarely caused hair loss, as it was not reported as a side effect in the studies included for review.

In a small clinical study of patients taking Rituxan for pemphigus vulgaris, 13% of patients taking Rituxan together with prednisone reported hair loss as a side effect. This was compared to 0% of patients taking prednisone alone. Hair loss was not commonly reported in studies of patients taking Rituxan for other health conditions.

As of March 2024, there have been 1,656 reports of hair loss by people taking Rituxan to the FDA Adverse Events Reporting System. However, these reports are not always complete. Many times it is not clear if the side effect reported is actually due to the medication, since people might be taking other medications at the same time. Additionally, there could be other causes of hair loss that are unrelated to any particular medication.

What should I do if I experience hair loss from Rituxan?

If you are taking Rituxan and notice hair loss or hair thinning, tell your healthcare provider. They can help you determine the cause of the hair loss and recommend appropriate strategies to manage it.

References

Belum, V. R., et. al. (2015). Alopecia in patients treated with molecularly targeted anticancer therapies. In: Annals of Oncology. DOI: https://doi.org/10.1093%2Fannonc%2Fmdv390

Cancer Research UK. (Updated Oct 2022). Rituximab. Accessed 07/13/2024 at https://www.cancerresearchuk.org/about-cancer/treatment/drugs/rituximab

FDA Adverse Events Reporting System (FAERS). US Food and Drug Administration (FDA). Accessed 07/13/2024 at https://fis.fda.gov/sense/app/95239e26-e0be-42d9-a960-9a5f7f1c25ee/sheet/45beeb74-30ab-46be-8267-5756582633b4/state/analysis

Mohebbi, N., et. al. (2022). Adverse drug reactions of Rituximab in patients suffering from autoimmune neurological diseases. In: DARU Journal of Pharamceutical Sciences. DOI: https://doi.org/10.1007%2Fs40199-022-00452-w

Puiu, T., et. al. (2022). Rituximab-Induced Alopecia Universalis in a Patient With Bullous Pemphigoid. In: Journal of Drugs in Dermatology. DOI: https://doi.org/10.36849/jdd.6690

Rituxan [package insert]. (Updated 2023). Genentech, Inc. Accessed 07/13/2024 at https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b172773b-3905-4a1c-ad95-bab4b6126563

Zhong, H., et. al. (2023). Clinical efficacy and safety of rituximab with membranous nephropathy: a meta-analysis. In: Archives of Medical Science. DOI: https://doi.org/10.5114%2Faoms.2020.99899

Read next

What are monoclonal antibodies?

Monoclonal antibodies (mAbs) are man-made proteins that mimic the natural antibodies produced by our immune systems. Monoclonal antibodies can be formulated into medicines to treat various types of illnesses, such as cancer, rheumatoid arthritis or psoriasis. Continue reading

What are biosimilar drugs and how do they compare to biologics?

A biosimilar is a biological product that is similar to a reference biologic (usually the originally approved product) and for which there are no clinically meaningful differences in terms of safety, purity, and potency. One example is Amjevita (adalimumab-atto), the first biosimilar approved for Humira (adalimumab) on September 23, 2016. Continue reading

What is the success rate of Rituxan (rituximab) in patients with blood cancers?

In patients with hematological or blood cancers, including non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL), Rituxan’s success is measured in a number of ways. It is measured by looking at how long patients responded to treatment (median duration of response), how long they live without their disease progressing (progression-free survival) and how many patients respond to treatment (response rate).

Rituxan treatment improves outcomes in certain patients with NHL. Adding Rituxan alongside standard therapies enhances the response patients have to treatment and improves overall outcomes, including increasing the time patients live for without experiencing a progression of their disease.

Rituxan helps to improve overall survival in certain patients with CLL and also helps to increase the time patients live for without experiencing disease progression. Adding Rituxan alongside standard therapy enhances the response patients have to therapy. Continue reading

Related medical questions

Drug information

Related support groups